​Integrated Asset Development for Optimizing Value and Outcomes
White Paper
​Evolving need for integrated asset value demonstration

Demonstrating product value is becoming more complex across therapeutic areas and impacting biotech, specialty and larger pharma alike. The key stakeholders involved in the ultimate success of a drug, and their evidence needs, continue to evolve as the marketplace transforms from volume- to value-based performance.